Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation

Sponsor
Clare Maguire (Other)
Overall Status
Unknown status
CT.gov ID
NCT03701035
Collaborator
Bildungszetrum Gesundheit Basel-Stadt (Other), Rehab Basel (Other)
30
1
2
19.8
1.5

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the influence on three different training modalities on the blood concentration levels of a growth factor called Brain Derived Neurotrophic Factor (BDNF) and on the recovery of arm function following in sub-acute and chronic stroke survivors. The training modalities are 1. moderate intensity aerobic training on a bike ergonometer followed by robotic or sensor-based upper-limb training, 2. non-aerobic circuit training followed by robotic or sensor-based upper-limb training 3. circuit training alone.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Aerobic Training & UL Motor Training
  • Behavioral: Non-aerobic training & UL Motor Training
N/A

Detailed Description

Background and Rationale:Brain-derived neurotrophic factor (BDNF) belongs to a group of neurotrophins which influence neuroplasticity by increasing long-term potentiation and axonal and dendritic growth. Levels of serum BDNF are increased following moderate intensity aerobic exercise (MAE) in animal and healthy subjects. The influence of MAE on BDNF following stroke and the resultant efficacy of motor training in this environment remains unclear.

Objective(s):To investigate the influence of MAE on acute and chronic levels of serum BDNF in sub-acute and chronic stroke patients, the efficacy of robotic upper limb or sensor based motor task training in this environment and consequent effect on functional arm recovery compared to the same upper limb training following non-aerobic training circuit training, or non-aerobic circuit training alone To evaluate the cost-effectiveness of the interventions. Study Interventions: Group 1: moderate intensity AE 40 minutes, 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb Training. Group2: non-aerobic gait and balance circuit training 40 mins 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb training, group 3: 40 minutes non-aerobic gait and balance circuit training.In total 45 participants will be enrolled - 15 in each group.Study Duration:3 monthly Intervention period per intervention group, with a 3 month and 6 month follow-up. .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Does Moderate Intensity Aerobic Training Influence Serum Levels of BDNF in Sub-acute and Chronic Stroke Patients and Consequently Increase the Efficacy of Upper-limb Rehabilitation? A Study Protocol for a Randomized Control Trial With an Embedded Health Economic Evaluation.
Actual Study Start Date :
Jan 8, 2019
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Sep 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Aerobic Training & UL Motor Training

Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks

Behavioral: Aerobic Training & UL Motor Training
Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®

Active Comparator: Non-aerobic Training & UL Motor Training

40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks

Behavioral: Non-aerobic training & UL Motor Training
40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®

Outcome Measures

Primary Outcome Measures

  1. BDNF [12 weeks]

    Acute (immediate post exercise) and chronic (post-intervention) serum BDNF levels

  2. Action Research Arm Test (ARAT) [12 weeks]

    A 19-Item standardised assessment of UL function measuring ADLs, coordination & dexterity.

Secondary Outcome Measures

  1. The Fugl-Meyer Assessment - Upper Extremity Scale (FMA). [12 weeks]

    Instrument for measuring upper limb impairment after stroke. The Fugl-Meyer Assessment - Upper Extremity Scale (FMA). This is reliable, responsive and valid instrument for measuring upper limb impairment after stroke. Items are scored on a three-point ordinal scale: 0=cannot perform, 1=performs partially, 2=performs fully. Maximal Score 66.

  2. 10 meter walking test [12 weeks]

    A measurement of gait speed

  3. Trunk Sway in standing with eyes closed [12 weeks]

    Standing balance

  4. The Montreal Cognitive Assessment (MoCA©). [12 weeks]

    This is a rapid screen of cognitive performance to detect mild cognitive dysfunction. The test consists of 16 items and 11 categories to assess multiple cognitive domains. The maximal score is 30.

  5. Corsi Block Test [12 weeks]

    Evaluates visuospatial short-term working memory

  6. The Fatigue Severity Scale (FSS) [12 weeks]

    Measures post-stroke-fatigue. This is a 9-item, 7 point linkert scale scale which measures the effect of fatigue on activities and lifestyle. The higher the score the worse the fatigue.

  7. Stroke Impact Scale [12 weeks]

    A disease specific Quality of Life measure.This is a 59 item measure in which 8 domains are assessed. Each item is a 5-point Linkert scale related to difficulty completing the scale . Summative scores are generated for each domain. A higher score indicates a better Performance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Hemiplegic stroke ischemic or intracerebral hemorrhagic > 3 months post- stroke

  • Active shoulder abduction, wrist and finger extension 10 degrees from a flexed position

Exclusion Criteria:
  • Contraindications to maximal exercise testing according to the American College of Sports Medicine guidelines

  • Severe perceptual problems

  • Concurrent neurological diagnoses e.g. Parkinsons disease

  • Comorbidities which may interfere with exercise participation

  • Significant cognitive impairment < 24 on the Montreal Cognitive Assessment Scale

Contacts and Locations

Locations

Site City State Country Postal Code
1 RehaB clinic for Neurorehabilitation and Paraplegiology Basel Switzerland 4055

Sponsors and Collaborators

  • Clare Maguire
  • Bildungszetrum Gesundheit Basel-Stadt
  • Rehab Basel

Investigators

  • Principal Investigator: Clare Maguire, PhD, Bern University of Applied Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Clare Maguire, Head of Master Programme Neurorehabilitation, Technical University of Bern
ClinicalTrials.gov Identifier:
NCT03701035
Other Study ID Numbers:
  • 2018-01249
First Posted:
Oct 9, 2018
Last Update Posted:
Feb 15, 2019
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2019